Open-Label Extension of EryDex Study IEDAT-04-2022 (OLE_NEAT)
An Open-Label Extension Study of EryDex in Patients With Ataxia Telangiectasia Following Participation in Study IEDAT-04-2022 (NEAT)
Sponsor: Biotrial
Terminated
eDSP development discontinued
Other terminated trials from Biotrial
Other Ataxia Telangiectasia trials with similar outcome
Listed as NCT06664853, this PHASE3 trial focuses on Ataxia Telangiectasia and remains terminated or withdrawn. Sponsored by Biotrial, it has been updated 12 times since 2024, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
▶ Show 7 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE3
-
Jun 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Nov 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Biotrial
- Quince Therapeutics S.p.A.
For direct contact, visit the study record on ClinicalTrials.gov .